Praxis Precision Stock Jumps 26% On Positive Results For Phase 2 Study Of Epilepsy Treatment

Shares of Praxis Precision Medicines, Inc. (PRAX) jumped over 26% on Tuesday morning after the company reported positive results from a phase 2 study of epilepsy treatment.

Related Keywords

Marcio Souza , Praxis Precision Medicines Inc , Nasdaq , Praxis Precision Medicines , Precision Medicines , Photo Paroxysmal Response , Praxis Precision ,